The Female Health Company


Image: company website


Female Condoms:

  • FC1® (no longer produced)
  • FC2®
  • FC3® (under development)

Company Type:

US Public Company on NASDAQ-CM under "FHCO" - Track Stock

Company Product Portfolio:

Female Condoms

Company Headquarters:

The Female Health Company
515 N. State Street, Suite 2225
Chicago, IL 60654

Key Contact Information:

UK Manufacturing Site

The Female Health Company
3 Mansfield Road
Western Avenue Business Park
W3 0BZ
United Kingdom
Tel: +44-208-993-4669

Malaysia Manufacturing Site (WHO/UNFPA Prequalified)

The Female Health Company (M) SDN BHD
No. 1A, Jalan CJ 1/4,
Kawasan Perindustrian Cheras Jaya
43200 Balakong. Selangor
Tel: +603 9076 2906/7

Company Overview:

The Female Health Company (FHC) manufactures, markets and sells the FC2 Female Condom® (FC2) female condom. In October 2009, the company completed the transition from its first generation product, FC1, to its second generation product, FC2, and production of FC1 ceased. Although FC1 production has ceased, FHC retains ownership of certain world-wide rights to FC1, as well as various patents, regulatory approvals and other intellectual property related to FC1.

FHC's female condoms have undergone extensive testing for efficacy, safety and acceptability in the United States and many countries around the world. Certain studies have shown that having FC available allows women and men to access more prevention options and results in an increase in protected sex acts and a decrease in STIs, including HIV/AIDS.

The FC2 is available in the United States and 143 countries around the world. The company owns certain worldwide rights to the FC2, including patents that have been issued in the U.S., the European Union, Canada, Australia, the Republic of South Africa. Japan, the People’s Republic of China, Spain, Mexico, Greece, Turkey and by the African Regional Intellectual Property Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Sudan, Swaziland, Uganda, Tanzania, Zambia and Zimbabwe. FC2 patent applications are pending in various other countries. The FC2 is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted infections (including HIV/AIDS), and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies (text taken and adapted from the Female Health Company website).

In addition to the manufacture and sales of female condoms, the Female Health Company also undertakes training and educational activities to help promote the usage of the FC2, and female condoms in general. This includes providing training resources on how to use the FC2 and also working with local partners to distribute and increase the uptake of the FC2 in individual countries. For more information see

For details on how FCMi collects and dissemintates market intelligence, refer to FCMi's Guidelines and Disclaimer.